Soleno’s rare pediatric disease drug faces PDUFA delay by three months
Soleno Therapeutics may have to wait longer to hear from the FDA on the potential approval of its first medicine.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
